Early and Late Arrhythmogenic Effects of Doxorubicin
Background: To determine the incidence of early and late arrhythmogenic effects of doxorubicin-containing chemotherapy regimens.
Patients and Methods: A prospective study including 29 patients who were treated with doxorubicin-containing regimens. Cardiac evaluation was based on 24-hour electrocardiographic monitorization (Holter), which was performed during the first cycle of doxorubicin-containing regimens, as well as after the last cycle of chemotherapy.
Results: The mean age of the patients was 45.8 ± 15.1 (range 18–69). Holter records obtained during the first cycle of treatment revealed varying arrhythmias in 19 patients (65.5%) and in 18 (62.1%) patients after completion of therapy. One patient presented with syncope and both Mobitz Type 2 atrioventricular block and complete atrioventricular block were demonstrated. The patient subsequently underwent permanent pacemaker implantation.
Conclusions: Doxorubicin may result in arrhythmias both in early and late periods of treatment. These arrhythmias are rarely life threatening.
* Cardiotoxicity is a well-known side effect of doxorubicin, a chemotherapeutic agent used in cancer treatment, and is frequently a dose-limiting factor.
* Doxorubicin-induced arrhythmia may be ventricular or supraventricular and can even present as a nonspecific electrocardiographic abnormality. Life-threatening arrhythmias rarely develop.
* In this study, we investigated doxorubicin-related arrhythmias, both in the early and late periods. Rhythm abnormalities recorded in both periods were similar, with the most common arrhythmia being supraventricular extrasystole.
* Doxorubicin is a cardiotoxic agent that can cause rhythm disturbances during or after its infusion and should be used with great caution.
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view your purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.